Literature DB >> 24071501

Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers.

Thomas E Kruger1, Andrew H Miller1, Andrew K Godwin2, Jinxi Wang3.   

Abstract

The mechanisms underlying malignant cell metastasis to secondary sites such as bone are complex and no doubt multifactorial. Members of the small integrin-binding ligand N-linked glycoproteins (SIBLINGs) family, particularly bone sialoprotein (BSP) and osteopontin (OPN), exhibit multiple activities known to promote malignant cell proliferation, detachment, invasion, and metastasis of several osteotropic cancers. The expression level of BSP and OPN is elevated in a variety of human cancers, particularly those that metastasize preferentially to the skeleton. Recent studies suggest that the "osteomimicry" of malignant cells is not only conferred by transmembrane receptors bound by BSP and OPN, but includes the "switch" in gene expression repertoire typically expressed in cells of skeletal lineage. Understanding the role of BSP and OPN in tumor progression, altered pathophysiology of bone microenvironment, and tumor metastasis to bone will likely result in development of better diagnostic approaches and therapeutic regimens for osteotropic malignant diseases.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Bone metastasis; Bone sialoprotein; Malignancy; Osteopontin

Mesh:

Substances:

Year:  2013        PMID: 24071501      PMCID: PMC3946954          DOI: 10.1016/j.critrevonc.2013.08.013

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  140 in total

Review 1.  Serum bone sialoprotein levels and bone metastases.

Authors:  Mario Uccello; Giulia Malaguarnera; Marco Vacante; Massimo Motta
Journal:  J Cancer Res Ther       Date:  2011 Apr-Jun       Impact factor: 1.805

2.  Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications.

Authors:  Brian Christensen; Mette S Nielsen; Kim F Haselmann; Torben E Petersen; Esben S Sørensen
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

3.  Osteopontin induces multiple changes in gene expression that reflect the six "hallmarks of cancer" in a model of breast cancer progression.

Authors:  Amy C Cook; Alan B Tuck; Susan McCarthy; Joel G Turner; Rosalyn B Irby; Gregory C Bloom; Timothy J Yeatman; Ann F Chambers
Journal:  Mol Carcinog       Date:  2005-08       Impact factor: 4.784

4.  The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model.

Authors:  A J Oates; R Barraclough; P S Rudland
Journal:  Oncogene       Date:  1996-07-04       Impact factor: 9.867

5.  Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.

Authors:  Deepak Agrawal; Tingan Chen; Rosalyn Irby; John Quackenbush; Ann F Chambers; Marianna Szabo; Alan Cantor; Domenico Coppola; Timothy J Yeatman
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

6.  CD44 cross-linking induces integrin-mediated adhesion and transendothelial migration in breast cancer cell line by up-regulation of LFA-1 (alpha L beta2) and VLA-4 (alpha4beta1).

Authors:  Hwai-Shi Wang; Ying Hung; Cheng-Hsi Su; Shu-Ting Peng; Yi-Jhih Guo; Mei-Chun Lai; Ching-Yi Liu; Jia-Wei Hsu
Journal:  Exp Cell Res       Date:  2004-11-26       Impact factor: 3.905

7.  Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion.

Authors:  Abdullah Karadag; Kalu U E Ogbureke; Neal S Fedarko; Larry W Fisher
Journal:  J Natl Cancer Inst       Date:  2004-06-16       Impact factor: 13.506

8.  Osteopontin silencing by small interfering RNA induces apoptosis and suppresses invasion in human renal carcinoma Caki-1 cells.

Authors:  Aimin Zhang; Yi Liu; Yizheng Shen; Youhe Xu; Xiangtie Li
Journal:  Med Oncol       Date:  2009-11-17       Impact factor: 3.064

Review 9.  Skeletal complications of malignancy.

Authors:  R E Coleman
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

10.  Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer.

Authors:  D Waltregny; A Bellahcène; I Van Riet; L W Fisher; M Young; P Fernandez; W Dewé; J de Leval; V Castronovo
Journal:  J Natl Cancer Inst       Date:  1998-07-01       Impact factor: 13.506

View more
  38 in total

1.  Correlation between calcification and bone sialoprotein and osteopontin in papillary thyroid carcinoma.

Authors:  Gang Wu; Jing-Jing Guo; Zhen-Yu Ma; Jie Wang; Zhong-Wen Zhou; Yi Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 2.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

Review 3.  Unique Metabolic Adaptations Dictate Distal Organ-Specific Metastatic Colonization.

Authors:  Tanya Schild; Vivien Low; John Blenis; Ana P Gomes
Journal:  Cancer Cell       Date:  2018-03-12       Impact factor: 31.743

Review 4.  Bone Metastasis: Find Your Niche and Fit in.

Authors:  Weijie Zhang; Igor Bado; Hai Wang; Hin-Ching Lo; Xiang H-F Zhang
Journal:  Trends Cancer       Date:  2019-01-17

Review 5.  Beyond cytokinesis: the emerging roles of CEP55 in tumorigenesis.

Authors:  J Jeffery; D Sinha; S Srihari; M Kalimutho; K K Khanna
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

6.  Lipid Osteoclastokines Regulate Breast Cancer Bone Metastasis.

Authors:  Jing Y Krzeszinski; Adam G Schwaid; Wing Yin Cheng; Zixue Jin; Zachary R Gallegos; Alan Saghatelian; Yihong Wan
Journal:  Endocrinology       Date:  2017-03-01       Impact factor: 4.736

Review 7.  The role of osteopontin in kidney diseases.

Authors:  Beata Kaleta
Journal:  Inflamm Res       Date:  2018-11-19       Impact factor: 4.575

8.  Effect of kidney-reinforcing and marrow-beneficial Chinese medicine on bone metabolism-related factors following spinal cord injury in rats.

Authors:  DA-An Zhou; Yue Ning Deng; Lei Liu; Jian Jun Li
Journal:  Exp Ther Med       Date:  2016-04-27       Impact factor: 2.447

9.  A cell-ECM screening method to predict breast cancer metastasis.

Authors:  L E Barney; E C Dandley; L E Jansen; N G Reich; A M Mercurio; S R Peyton
Journal:  Integr Biol (Camb)       Date:  2015-02       Impact factor: 2.192

Review 10.  Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis.

Authors:  Jingcheng Chen; Lei Zhou; Xuelian Liu; Xue Wen; Hui Li; Wei Li
Journal:  Int J Clin Pharm       Date:  2020-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.